Market Trends of Sarcoma Drugs Industry
Immunotherapy is Expected to Register Significant Growth Over the Forecast Period
- Immunotherapy is a type of treatment that uses medications to help a person's immune system recognize and destroy cancer cells more effectively. The segment is expected to witness significant growth during the forecast period due to the increasing number of clinical trials and the approval of immunotherapy drugs for sarcomas.
- Numerous clinical trials are being conducted to study the effectiveness of immunotherapy for different types of sarcomas, either independently or in combination with other treatments. For example, in January 2021, a clinical trial was initiated to evaluate the efficacy of adoptive immunotherapy in relapsed and non-resectable sarcomas after multimodal treatment. The trial is currently in Phase 1, and the estimated completion date is January 2024. According to clinicaltrials.gov, as of January 2023, there are 44 active trials for immunotherapy for sarcomas, with the status of recruiting, active, not recruiting, and enrolling by invitation studies. Thus, the increasing number of clinical trials studying immunotherapy for treating sarcomas is expected to drive the growth of this segment.
- Furthermore, the strategic initiatives taken by market players, such as product launches, approvals, and partnerships, are expected to boost the segment's growth. For instance, in December 2022, the United States Food and Drug Administration (US FDA) approved atezolizumab or Tecentriq, manufactured by Roche's Genentech, Inc., for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). This cancer immunotherapy can reactivate the immune system, enabling it to identify cancer cells in the body. Such approvals of advanced immunotherapy drugs for sarcomas are expected to fuel the growth of the segment during the forecast period.
- In conclusion, the high number of clinical trials for immunotherapy and the increasing approvals of immunotherapy drugs are anticipated to propel the growth of this segment during the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Market Share Over The Forecast Period
- North America is expected to hold a significant share of the sarcoma drugs market. This is primarily due to several factors, such as the high burden of sarcomas in the region, increasing research and development activities by market players to develop innovative sarcoma drugs, rising patient assistance programs, better healthcare infrastructure, and the strong presence of industry players.
- According to the American Cancer Society's 2022 update, approximately 13,190 new cases of soft tissue sarcomas were expected to be diagnosed in the United States in 2022, with 7,590 cases in males and 5,600 cases in females. The high burden of sarcomas in the region is expected to propel market growth.
- Moreover, government organizations fund various research studies to conduct trials on small or large patient pools to assess the safety and efficacy of sarcoma interventions. For example, in August 2021, researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI) and part of the National Institutes of Health (NIH), conducted a study of 16 patients with the rare cancer angiosarcoma. Four individuals had malignancies that either entirely or partially responded to treatment with a combination of the immunotherapy drugs nivolumab and ipilimumab. Such research studies are expected to pave the way for the development of innovative sarcoma drugs that will propel market growth in the region during the forecast period.
- Therefore, the North American market for sarcoma drugs is expected to grow significantly due to the high burden of sarcomas and increasing R&D activities in the region, leading to the development of innovative sarcoma therapies.
Get Analysis on Important Geographic Markets
Download PDF
